Programmatic control of multidrug-resistant tuberculosis

Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach, Third Edition

Volumn , Issue , 2006, Pages 845-867

  Cegielski, Peter ^a   Jaramillo, Ernesto ^b   Blöndal Vink, Kai ^c   Lambregts Van Weezenbeek, Kitty ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953655349     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3(suppl 2):S231-S252.
2. Medical Research Council: Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. Br Med J 1949; 2:1521-1525.
3. Medical Research Council: Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Br Med J 1955; 7:435-445.
4. Rist N. The application to clinical practice of the laboratory experience with combinations of antituberculosis drugs. Bull Int Union Tuberc 1953; 23:416-427.
5. Wolinsky E, Reginster A, Steenken W Jr. Drugresistant tubercle bacilli in patients under treatment with streptomycin. Am Rev Tuberc 1948; 58:335-343.
6. Iseman MD. Tuberculosis chemotherapy, including directly observed therapy. In: Iseman MD. A Clinician’s Guide to Tuberculosis. Philadelphia: Lippincott Williams and Wilkins, 2000:271-322.
7. Dooley SW. Multidrug-resistant tuberculosis. Ann Int Med 1992; 117:257-258.
8. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance Anti-tuberculosis drug resistance in the world. First global report. Geneva: World Health Organization, 1997 (WHO/TB/97.229).
9. The WHO/IUTLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Second global report. Geneva: World Health Organization, 2000 (WHO/CDS/TB/2000.278).
10. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world: third global report. 1999-2002. Geneva: World Health Organization, 2004 (WHO/HTM/TB/2004.343).
11. Iseman MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy 1999; 45(suppl 2):34-40.
12. Gupta R, Kim JY, Espinal MA, Caudron JM, Farmer PE, Raviglione MC. Responding to market failures in tuberculosis: a model to increase access to drugs and treatment. Science 2001; 293:1049-1051.
13. Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Int Health 2002; 7:970-976.
14. Stop TB Partnership and World Health Organization. Global Plan to Stop TB 20062015. Geneva, Switzerland: World Health Organization, 2006 (WHO/HTM/STB/2006.35).
15. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 2006 (WHO/HTM/TB/2006.361).
16. Bates JH, Stead WW. The history of tuberculosis as a global epidemic. Med Clin North Am 1993; 77:1205-1217.
17. Styblo K. The Epidemiology of Tuberculosis. Vol. 24. Of KNCVs. eds, Selected Papers. The Hague, The Netherlands: Royal Netherlands Tuberculosis Association, 1991.
18. Kim J, Mate K, Rich ML, Mukherjee JS, Bayona J, Becerra MC. From Multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis 2003; 83:59-65.
19. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9:640-645.
20. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programs. 3rd ed., revised (WHO/CDS/TB 2003.313/rev,). Geneva, Switzerland: World Health Organization, 2004.
21. Leimane V, Riektsina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365:318-326.
22. Bayona J et al. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2003; 7:S501-S509.
23. Francis J. Curry National Tuberculosis Center. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. Sacramento, California::Department of Health Services, 2004; 33-49, 55-175.
24. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796-806.
25. Dye C. Global TB epidemiology and progress toward the Millennium Development Goals. Joint Meeting of the DOTS Expansion, TB/HIV and DOTS-Plus Working Groups in Memory of Lisa Veron. Symposium of the 36th World Conference on Lung Health, Paris, France, October 18, 2005.
26. Jarvis WR et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. Res Microbiol 1993; 144:117-122.
27. Herrera D, Cano R, Godoy, et al. Multidrug-resistant tuberculosis outbreak on an HIV ward - Madrid, Spain, 1991-1995. MMWR 1996; 45:330-333.
28. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176:637-642.
29. Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. AIDS 1998; 12:1095-1102.
30. Harvard Medical School/Open Society Institute. The Global Impact of Drug Resistant Tuberculosis. Boston: Program in Infectious Diseases and Social Change, Harvard Medical School, 1999:1-179.
31. WHO, IUATLD. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998; 2:71-89.
32. WHO, IUATLD. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: World Health Organization, 2003 (WHO/CDS/TB/2003.320).
33. Laszlo A, Rahman M, Raviglione M, Bustreo F, WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug-susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1:231-238.
34. Laszlo A, Rahman M, Espinal M, Raviglione M. Quality assurance programme for drug-susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6:748-756.
35. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5(10):887-893.
36. Quy HT et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7:631-636.
37. Kritski AL, Rodrigues de Jesus LS, Andrade MK, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111:1162-1167.
38. Bone A, Aerts A, Grzemska M, et al. Tuberculosis Control in Prisons: A Manual for Programme Managers. Geneva: WHO/IFRC, 2000 (WHO/CDS/TB/2000.281).
39. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3:582-588.
40. CDC. Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996; 45(No. RR-8):1-25.
41. CDC. Primary multidrug-resistant tuberculosis—Ivanovo Oblast, Russia, 1999. MMWR 1999; 48:661-664.
42. Scientific Panel of the Working Group on DOTS-Plus for MDR-TB. Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug-Resistant Tuberculosis (MDR-TB). Geneva: WHO, 2000 (WHO/CDS/TB/2000.279).
43. Stop TB Partnership. The Global Plan to Stop Tuberculosis: Phase 1: 2000-2005. Geneva, Switzerland (WHO/CDS/STB/2001.16).
44. WHO. Instructions for Applying to the Green Light Committee for Access to Second-Line Anti-TB Drugs, 2002. WHO/CDS/TB/2001.286 Rev.1. Available at: http://whqlibdoc.who.int/hq/2001/WHO_CDS_TB_2001.286_Rev.Lpdf (accessed 23 Jan 06) and at: http://www.who.int/tb/dots/dotsplus/management/en/index.html (accessed 23 Jan 06).
45. Nathanson E, Lambregts K, Rich M, et al. Successful management of multidrug-resistant (MDR) tuberculosis (TB) in resource-limited setting. Emerging Infections Diseases (in press).
46. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8:1382-1384.
47. WHO. Procurement Manual for DOTS-Plus Projects Approved by the Green Light Committee. Geneva: WHO, 2003 (WHO/HTM/TB/2003.328).
48. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2005. Geneva: World Health Organization (WHO/HTM/TB/2005.349), p. 41.
49. Shah NS, Wright A, Drobniewski F, et al. Extreme drug resistance in tuberculosis (‘XDR TB’): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Abstract PS-1560-20. 36th World Conference on Lung Health, Paris, France, 18-22 October 2005.
50. Laserson KF, Binkin NJ, Thorpe LE, et al. Capacity building for international tuberculosis control through operations research training. Int J Tuberc Lung Dis 2005; 9:145-150.